Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer’s drug raises ‘good’ cholesterol lowers ‘bad’

Pfizer’s drug raises ‘good’ cholesterol lowers ‘bad’

25th November 2005

A new drug, developed by Pfizer, has been found to reduce the presence of “bad” cholesterol but increase the amount of “good” cholesterol in the blood stream.

Two phase II studies, presented to the American Heart Association, looked at whether the new drug torcetrapib, combined with atorvastatin (also known as Lipitor), can increase the amount of HDL-C cholesterol in the blood while lower “bad” LDL-C cholesterol levels.

HDL-C is known to remove cholesterol from cells, preventing a build up which could contribute to heart disease. Torcetrapib was found to increase levels of HDL-C by 44 to 66 per cent, whilst LDL-C levels were reduced by 41 to 60 per cent. The study looked at 500 patients.

“These results demonstrate that torcetrapib/atorvastatin can dramatically raise HDL while providing LDL-lowering benefits greater than Lipitor alone,” said Pfizer’s chief medical officer Dr Joseph Feczko.

“These results were pivotal in our decision to move forward with a Phase 3 program, the final stage in clinical development. If this program is successful, this new approach could change the way physicians manage cholesterol,” he added.

Torcetrapib is said to work by inhibiting the protein CETP, which transfers triglycerides and cholesterol between LDL and HDL in the blood.

track© Adfero Ltd

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.